Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.

Manon BelhassenOlivier HanonPhilippe Gabriel StegIsabelle MahéMélanie NéeFlore JacoudFaustine DalonFrançois-Emery CottéDominique Guitard-DehouxClaire Marant-MicallefEric Van GanseNicolas Danchin

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2022)

HCRU and most event-related costs were lower in patients initiating apixaban compared to other OACs. Apixaban may be cost-saving compared to VKAs, and significantly cheaper than other DOACs, although cost differences are limited.

Keyphrases

atrial fibrillation
venous thromboembolism
direct oral anticoagulants
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
left atrial appendage
patient reported outcomes
patient reported